News

Roper Technologies (ROP), What Is Behind The Fresh Attention?

Roper Technologies (ROP) is back in focus after releasing third quarter results showing higher sales, earnings and per share profits, alongside fresh guidance for the fourth quarter and full year 2026. That earnings beat has coincided with a sharp shift in sentiment, with a 7 day share price return of 15.16% and a 30 day gain of 23.17% pushing Roper Technologies to US$441.65, even though the 1 year total shareholder return is still down 3.84%. Scan how Roper Technologies compares with other...

Yahoo·08:08ROP▼−2.2%

Roper Technologies: 3 Key Takeaways for Long-Term Investors

With $6 billion in deployment capacity and mid-90s software retention, Roper has both the firepower and the moat to compound shareholder returns through disciplined M&A.

Yahoo·17:34ROP▼−2.2%

Roper Technologies Analyst Turns Bullish After Q3 Print

JPMorgan upgraded Roper to Neutral rating and raised its target citing organic growth, earnings and software M&A outlook.

Benzinga·08:44ROP▼−2.2%

Can Roche Holding (SWX:ROP) Still Be Cheap After Fresh Trial Wins?

Roche Holding has delivered a strong multi year share price run, helped by a busy drug pipeline and fresh clinical data. This raises a simple question for you as an investor: Is the current price still aligned with what the business is earning today? Roche Holding has returned 82.3% over the past 3 years, so a lot of optimism about its earnings power is already reflected in the recent share price story. Recent Phase III results in kidney disease and neuroimmunology, plus new collaborations...

Yahoo·12:14ROP▼−2.2%

Jefferies Maintains Buy on Roper Technologies, Raises Price Target to $540

Jefferies analyst Brent Thill maintains Roper Technologies (NASDAQ:ROP) with a Buy and raises the price target from $500 to $540.

Benzinga·12:48ROP▼−2.2%

Citigroup Maintains Buy on Roper Technologies, Raises Price Target to $525

Citigroup analyst George Kurosawa maintains Roper Technologies (NASDAQ:ROP) with a Buy and raises the price target from $450 to $525.

Benzinga·10:40ROP▼−2.2%

Truist Securities Maintains Buy on Roper Technologies, Raises Price Target to $500

Truist Securities analyst Terry Tillman maintains Roper Technologies (NASDAQ:ROP) with a Buy and raises the price target from $475 to $500.

Benzinga·09:53ROP▼−2.2%

RBC Capital Maintains Sector Perform on Roper Technologies, Raises Price Target to $450

RBC Capital analyst Rishi Jaluria maintains Roper Technologies (NASDAQ:ROP) with a Sector Perform and raises the price target from $417 to $450.

Benzinga·06:26ROP▼−2.2%

Roper (ROP) Stock May Be 16% Undervalued On Cash Flow

Roper Technologies has rallied sharply in recent weeks, which puts the focus squarely on whether the current share price lines up with what its cash flows can justify. For anyone following the stock, the question now is whether that move is supported by the cash the business is expected to generate over time. The share price has risen 19.9% over the past month, which puts more pressure on the underlying cash flow story to support where Roper Technologies now trades. The company focuses on...

Yahoo·19:13ROP▼−2.2%

Roper Stock Surges on Earnings Beat. Investors See Promise in Its AI Push.

Adjusted earnings rose 15% to $5.89 a share, beating expectations.

Yahoo·16:24ROP▼−2.2%

Roper (ROP) Q3 2026 Earnings Call Transcript

Software momentum drove 7% organic growth as management raised full-year guidance.

Yahoo·14:15ROP▼−2.2%

Roper Technologies Soars 9.2% on Earnings Beat and Guidance Raise: “Exceeded Our Expectations”

Key TakeawaysRoper Technologies shares jumped 9. 2% today after third-quarter adjusted EPS of $5.

Yahoo·13:18ROP▼−2.2%

Roper Technologies Q3 Earnings Call Highlights

Roper Technologies (NASDAQ:ROP) reported third-quarter 2026 results marked by 7% organic revenue growth, 15% adjusted diluted earnings-per-share growth and continued investment in artificial intelligence products and bolt-on acquisitions. Revenue rose 8% year over year to $2.2 billion, while EBITDA

Yahoo·11:05ROP▼−2.2%

ROP Q3 Earnings Beat Estimates on Solid Organic Growth

Roper beats Q3 earnings estimates as 7% organic revenue growth fueled all three segments, while higher 2026 earnings guidance signals continued growth.

Yahoo·10:50ROP▼−2.2%

Roper Technologies (ROP) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Roper Technologies (ROP) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Yahoo·08:30ROP▼−2.2%

Roper Technologies (NASDAQ:ROP) Q3 2026: In-Line Results and Raised EPS Guidance Meet a Muted Market Reaction

Roper Q3 2026 results met estimates; FY adjusted EPS guidance raised. Shares slipped premarket after a strong run. Read key earnings takeaways.

ChartMill·08:27ROP▼−2.2%

Roper Technologies (ROP) Q3 Earnings Beat Estimates

Roper Technologies (ROP) delivered earnings and revenue surprises of +1.73% and -0.26%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo·07:15ROP▼−2.2%

Roper Technologies: Q3 Earnings Snapshot

(ROP) on Thursday reported third-quarter profit of $484.On a per-share basis, the Sarasota, Florida-based company said it had net income of $4.

Yahoo·07:04ROP▼−2.2%

Roper Technologies Announces Third Quarter Financial Results

Increases full year DEPS guidanceSARASOTA, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) reported financial results for the third quarter ended September 30, 2026. Third quarter 2026 highlights Revenue increased 8% to $2.17 billion; organic revenue was +7% and acquisition contribution was +1%GAAP net earnings increased 22% to $485 million; adjusted net earnings increased 5% to $586 millionAdjusted EBITDA increased 7% to $864 millionGAAP DEPS increased 33% to $4.8

Yahoo·06:55ROP▼−2.2%

What Could Roche Holding (SWX:ROP) Reveal With New Phase III Cancer Data?

Roche Holding (SWX:ROP) and Genentech plan to present new Phase III lung and breast cancer data at the 2026 ESMO Annual Meeting. The late-stage divarasib results focus on lung cancer, providing fresh evidence on a next-generation targeted therapy approach. Giredestrant Phase III findings in breast cancer are set for a late-breaking session, highlighting updated outcomes in hormone-driven disease. The divarasib and giredestrant Phase III readouts only tell part of the story for Roche's...

Yahoo·13:14ROP▼−2.2%

Roper Technologies (ROP) Upgraded to Buy: Here's Why

Roper Technologies (ROP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo·11:00ROP▼−2.2%

Roper Technologies Set to Report Q3 Earnings: What's in the Cards?

ROP heads into Q3 earnings with projected revenue growth of 7.9% and EPS growth of 12.7%, but rising costs and FX headwinds pose challenges.

Yahoo·08:56ROP▼−2.2%

Roche Holding (SWX:ROP) Licensed An ALK7 RNAi Obesity Therapy

Roche Holding (SWX:ROP) has agreed an exclusive global licence with Rona Therapeutics for an ALK7-targeting RNAi obesity therapy. The licensed RNA interference drug is designed to act in adipose tissue and aims to cut visceral fat while preserving lean mass. The collaboration extends Roche's presence in RNA based treatments for metabolic diseases by using Rona Therapeutics' RNAi platform. Roche's ALK7 RNAi licensing deal with Rona sits alongside other factors that shape the wider picture for...

Yahoo·15:11ROP▼−2.2%

Roper Technologies (ROP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Roper Technologies (ROP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo·09:00ROP▼−2.2%

Roche Holding (SWX:ROP) Reports Phase III Vamikibart Data In Uveitic Macular Edema

Genentech, part of Roche Holding (SWX:ROP), reported new Phase III results for vamikibart in uveitic macular edema (UME). The data suggest vamikibart could become the first non steroid targeted therapy option for this severe cause of vision loss. The FDA has accepted a Biologics License Application for vamikibart in UME, with a decision currently scheduled for 2027. These Phase III vamikibart results and the FDA filing only capture one side of Roche Holding's risk and opportunity mix. Our...

Yahoo·06:12ROP▼−2.2%

Roper Technologies' PowerPlan Announces Launch Of PowerPlan Enterprise Adapter For Oracle Fusion Cloud ERP

PowerPlan, a leading provider of financial software solutions for asset-intensive companies, today announced the launch of the PowerPlan Enterprise Adapter for Oracle® Fusion Cloud ERP. The new Adapter gives customers

Benzinga·03:20

Why Roper Technologies (ROP) is Poised to Beat Earnings Estimates Again

Roper Technologies (ROP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Yahoo·11:10ROP▼−2.2%

Roche Holding (SWX:ROP) Ebola Testing Support Keeps Fair Value In Focus

Roche Holding (SWX:ROP) has been back in focus after Roche Diagnostics shipped two molecular testing instruments to support Ebola response efforts in the Democratic Republic of Congo, tying humanitarian work directly to the diagnostics segment. Against this backdrop, Roche Holding shares trade at CHF352.7 after a 1-day share price return that declined 2.03%. The 90-day share price return of 4.78% and 1-year total shareholder return of 23.81% indicate that momentum has been gradually building...

Yahoo·20:20ROP▼−2.2%

What Roper Technologies (ROP)'s AI-Focused Board Addition and Bigger Buybacks Strategy Shift Means For Shareholders

Roper Technologies recently appointed Abhijit Dubey, Chief Executive Officer and Chief AI Officer of NTT DATA, Inc., to its Board of Directors for a term running through the 2027 Annual Meeting of Stockholders, adding deep cloud and artificial intelligence expertise to its governance bench. Alongside this board refresh, Roper signaled a stronger focus on internal value creation by expanding its share repurchase activity and lifting revenue guidance, underpinned by recurring software revenue...

Roche (SWX:ROP) Stock Looks Undervalued Despite Recent Pipeline Progress

Roche Holding has delivered a strong multi year share price run, and with the stock last closing at CHF 360.00 the live question is whether that price still lines up with what its earnings support. Recent product milestones and licensing deals keep reshaping the story, so the issue for you is how much of that is already reflected in the earnings multiple today. Roche Holding has returned 57.1% over the past 3 years, which puts real weight on the question of whether its current P/E is...

Yahoo·05:08ROP▼−2.2%

Is Roper Technologies (ROP) Trading At A Discount To Cash Flow?

Roper Technologies has had a rough stretch on the market, which raises a straightforward question for you as an investor: Is the current share price still in line with what the company’s cash flows can justify? The stock is down 30.4% over the past year, which puts the focus squarely on whether that drop now better reflects the value of its underlying cash generation. Management has leaned into share repurchases and higher earnings expectations, a shift that can change how much future cash...

Yahoo·19:17ROP▼−2.2%

Roche launches newborn screening test for three severe genetic conditions

Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepting the CE mark. The test simultaneously screens for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD). This launch provides a crucial, ready-to-use solution for private and academic hospital labs, enabling the ea

Yahoo·01:00ROP▼−2.2%

CTSH or ROP: Which Is the Better Value Stock Right Now?

CTSH vs. ROP: Which Stock Is the Better Value Option?

Yahoo·10:40ROP▼−2.2%

Roche Holding (SWX:ROP) Signed New AI Drug Discovery Partnerships

Roche Holding (SWX:ROP) announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. The group signed a research partnership with Earendil Labs to apply AI to bispecific antibody cancer therapies across multiple tumor types. Roche agreed a collaboration with Atavistik Bio to pursue allosteric small molecules for cardiovascular, renal and metabolic conditions. Enicepatide (CT-388) reported positive Phase 2 results in type 2 diabetes and...

Yahoo·16:06ROP▼−2.2%

Roche (SWX:ROP) Stock Looks Discounted As Its 60% Run Continues

Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. With a string of positive late stage trial results in oncology, neurology and renal disease, the question for you now is how much of that clinical momentum is already reflected in the price. Roche Holding has returned 59.8% over the past 3 years, so a lot of future expectations are already embedded in the current...

Yahoo·19:14ROP▼−2.2%

Is Roche Holding (SWX:ROP) Undervalued Following Its Phase 3 IgA Nephropathy Win?

Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The latest clinical headlines come on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date. The 1-year total shareholder return of 44.02% points to momentum that has been building rather than...

Yahoo

Roche Holding (SWX:ROP) Phase III Trial Met Its Primary Endpoint In Follicular Lymphoma

Roche Holding (SWX:ROP) reported that its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. The CELESTIMO data support regulatory submissions to expand Lunsumio’s label to patients who have received at least one prior systemic therapy. Roche highlighted that the Lunsumio and lenalidomide combination is designed for outpatient administration, aiming to ease capacity pressure on hospitals. The CELESTIMO outcome for...

Yahoo·11:11ROP▼−2.2%

Illumia Appoints Don Smith to Lead Higher Education Portfolio

SCOTTSDALE, Ariz., September 15, 2026--Illumia, a leading provider of technology solutions that power payments, identity, commerce and foodservice operations across higher education, healthcare and corporate campuses, today announced the appointment of Don Smith to senior vice president & general manager, higher education. Smith will work across product, technology, commercial and customer teams to better connect Illumia’s products and experiences. The goal is to make it easier for colleges and

Yahoo·10:00

DAT: Spot van rate falls 20 cents in steepest August pullback on record

PORTLAND, Ore., Sept. 15, 2026 (GLOBE NEWSWIRE) -- National average truckload spot rates fell across all three equipment types in August, posting the steepest July-to-August declines in DAT’s 16-year rate history, according to DAT Freight & Analytics, provider of the industry’s leading load boards and freight analytics. The pullback also moved dry van and refrigerated (“reefer”) spot rates back below contract rates after spot rates exceeded contract rates in June and July. Spot rates post record

Yahoo·09:30

Roper Technologies, Inc. (ROP) Presents at Piper Sandler 5th Annual Growth Frontiers Conference Transcript

Roper Technologies, Inc. (ROP) Piper Sandler 5th Annual Growth Frontiers Conference September 15, 2026 9:30 AM EDTCompany ParticipantsJason Conley -...

SeekingAlpha·08:31ROP▼−2.2%

Procare Solutions Acquires Playground, Combining Industry Leading Expertise with Innovative, AI-Powered Child Care Technology

Procare Solutions, a leader in AI-enabled child care management software, trusted by more than 40,000 centers nationwide, announced today it has acquired Playground, a modern, all-in-one child care management platform recognized for its intuitive design, top-rated customer support and AI-powered tools, including Camber, the first AI assistant purpose-built for child care.

Yahoo·11:00

Roper Technologies, Inc. (ROP) Presents at Citi's 2026 Global TMT Conference Transcript

Roper Technologies, Inc. (ROP) Citi's 2026 Global TMT Conference September 10, 2026 8:50 AM EDTCompany ParticipantsJason Conley - Executive VP & CFONeil...

SeekingAlpha·07:27ROP▼−2.2%

Roper Technologies, Inc. (ROP) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript

SeekingAlpha·10:47ROP▼−2.2%

Why Roche Holding (SWX:ROP) Is Getting Attention Today

Roche Holding (SWX:ROP) has been back in focus after Treeline Biosciences agreed to a clinical trial collaboration that combines TLN-121 with Roche bispecific antibodies glofitamab and mosunetuzumab for B-cell lymphomas. Roche Holding shares trade at CHF357.0, with a 90-day share price return of 10.63% and a year-to-date share price return of 9.68%. The 1-year total shareholder return of 34.18% points to momentum that has built alongside a steady stream of oncology and diagnostics...

Yahoo·19:12ROP▼−2.2%

Roche (SWX:ROP) Stock Looks Reasonable On Earnings But Mixed On Value

Roche Holding stock has delivered a solid multi year gain, yet the valuation signals are more mixed, which leaves investors weighing a strong price record against a less clear cut verdict on how cheap the shares really are. After a 3 year climb, the stock now screens as neither an obvious bargain nor clearly expensive. Roche Holding has returned about 54.2% over the past 3 years, which puts extra focus on whether that share price performance already reflects most of the good news in the...

Yahoo·

Roche Holding (SWX:ROP) Received FDA Clearance For An Alzheimer’s Blood Test

Roche Holding (SWX:ROP) announced a collaboration with Treeline Biosciences to study combination immunotherapies for B-cell lymphomas. The partners plan to evaluate advanced immune based treatments aimed at improving options for lymphoma patients. Roche received FDA clearance for its Elecsys pTau217 blood test as the first single biomarker assay to help both rule in and rule out amyloid pathology in Alzheimer’s disease. The Elecsys pTau217 test is intended to support clinicians in earlier...

Yahoo·19:05ROP▼−2.2%

Roper Technologies to present at Citi Technology Conference

SARASOTA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that it is presenting at the Citi Global TMT Conference on Thursday, September 10, 2026, at 8:50 AM (Eastern Time). A link to the webcast presentation will be available in the “Investors” section of the Company’s website at www.ropertech.com. About Roper Technologies Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 500. Roper has a proven, long-term track record of compo

Yahoo·09:30ROP▼−2.2%

Roper Technologies to present at Goldman Sachs Technology Conference

SARASOTA, Fla., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that it is presenting at the Goldman Sachs Communacopia + Technology Conference on Wednesday, September 9, 2026, at 8:10 AM (Pacific Time). A link to the webcast presentation will be available in the “Investors” section of the Company’s website at www.ropertech.com. About Roper Technologies Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 500. Roper has a proven, long-te

Yahoo·09:30ROP▼−2.2%

Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023.

Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.

Yahoo·14:44

Illumia Names Sean Bruton as Chief Information Security Officer

SCOTTSDALE, Ariz., September 01, 2026--Illumia, a leading provider of technology solutions that power payments, identity, commerce and foodservice operations across higher education, healthcare and corporate campuses, today announced the appointment of Sean Bruton as Chief Information Security Officer (CISO). Bruton brings more than 25 years of experience in cybersecurity and compliance leadership, including experience building compliance technology, leading managed security services, and using

Yahoo·11:00

3 Dividend Stocks with Unbelievable Streaks but Barely Pay Investors

Some dividend stocks boast decades of unbroken raise streaks yet leave income investors with almost nothing to show for it. These three companies sit in that strange category, and the tension between their legendary consistency and their near-invisible payouts reveals something important about what a dividend streak actually means.

Yahoo·11:47

Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore

Columvi® (glofitamab) will be added to the Singapore Ministry of Health's (MOH) CDL and MAF List. Starting 1 September 2026, this milestone ensures that eligible Singaporeans and Permanent Residents will have subsidised access to the medication in public healthcare institutions.[1]

Yahoo·22:00

Roche Holding (SWX:ROP) Secures FDA Clearance For Alzheimer’s Blood Test

Roche Holding (SWX:ROP) received FDA approval for its Elecsys pTau217 blood test for Alzheimer's disease in the U.S. The Elecsys pTau217 test is designed to identify amyloid pathology using a blood sample, widening access to dementia diagnostics across U.S. labs. The FDA also cleared expanded use of Roche's PATHWAY HER2 and VENTANA HER2 Dual ISH tests in metastatic gastroesophageal cancers. These approvals broaden options for HER2 testing in cancer care and support more tailored treatment...

Yahoo·18:07ROP▼−2.2%

CoStar (CSGP) Up 7.7% Since Last Earnings Report: Can It Continue?

CoStar (CSGP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo·12:30

Roper Technologies: A Cautious Buy Despite The Risks

Roper's Q2 8.5% revenue growth and a 233% EPS increase were driven by equity gains from Indicor and robust segment performance. Read why ROP stock is a Buy.

SeekingAlpha·17:01ROP▼−2.2%